S

S2Medical AB (publ)
STO:S2M

Watchlist Manager
S2Medical AB (publ)
STO:S2M
Watchlist
Price: 0.0085 SEK Market Closed
Market Cap: 7.1m SEK
Have any thoughts about
S2Medical AB (publ)?
Write Note

S2Medical AB (publ)
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

S2Medical AB (publ)
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
S
S2Medical AB (publ)
STO:S2M
Capital Expenditures
-kr1.1m
CAGR 3-Years
28%
CAGR 5-Years
21%
CAGR 10-Years
N/A
O
OssDsign AB
STO:OSSD
Capital Expenditures
-kr124k
CAGR 3-Years
63%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Xvivo Perfusion AB
STO:XVIVO
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
D
Doxa AB
STO:DOXA
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bactiguard Holding AB
STO:BACTI B
Capital Expenditures
-kr8.6m
CAGR 3-Years
18%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
V
Vimian Group AB
STO:VIMIAN
Capital Expenditures
-€15.2m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

S2Medical AB (publ)
Glance View

Market Cap
7.1m SEK
Industry
Health Care

S2Medical AB engages in research and development in biotechnology. The company is headquartered in Linkoping, Ostergotland. The company went IPO on 2018-11-28. The firm focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The firm's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The firm is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.

S2M Intrinsic Value
0.0322 SEK
Undervaluation 74%
Intrinsic Value
Price
S

See Also

What is S2Medical AB (publ)'s Capital Expenditures?
Capital Expenditures
-1.1m SEK

Based on the financial report for Jun 30, 2024, S2Medical AB (publ)'s Capital Expenditures amounts to -1.1m SEK.

What is S2Medical AB (publ)'s Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
21%

Over the last year, the Capital Expenditures growth was 14%. The average annual Capital Expenditures growth rates for S2Medical AB (publ) have been 28% over the past three years , 21% over the past five years .

Back to Top